What’s the current market cap for Zymeworks stock?

Zymeworks (ZYME) has a market cap of $1.7bn as of June 12, 2026.

What is the P/E ratio for Zymeworks stock?

The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of June 12, 2026.

Does Zymeworks stock pay dividends?

No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of June 12, 2026.

When is the next Zymeworks dividend payment date?

Zymeworks (ZYME) stock does not pay dividends to its shareholders.

What is the beta indicator for Zymeworks?

Zymeworks (ZYME) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Zymeworks stock | $ZYME Share Price

13:30

15:10

16:45

18:25

20:00

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Ticker

$ZYME

Sector

Health

Primary listing

NASDAQ

Employees

243

Headquarters

Middletown, United States

Website

www.zymeworks.com

Zymeworks Metrics

BasicAdvanced

$1.7bn

-$1.36

1.19

What the Analysts think about Zymeworks

Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.

Bulls say / Bears say

The FDA accepted and granted Priority Review to the supplemental BLA for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma, establishing a PDUFA target date of August 25, 2026—a key near-term regulatory milestone. (Reuters)

In March 2026, Zymeworks secured $250 million in non-recourse royalty-backed note financing from Royalty Pharma, strengthening its balance sheet and extending its cash runway beyond 2028 without further shareholder dilution. (Reuters)

Q1 results showed strong internal pipeline progress, including positive Phase 1 data for ZW191 in platinum-resistant ovarian cancer (56% ORR) and novel RAS-targeting ADC candidates presented at AACR, highlighting diversified growth opportunities. (Nasdaq)

Q1 2026 revenue dropped sharply to $2.4 million from $27.1 million a year earlier, mainly due to one-off milestone payments in 2025, showing that current revenue streams remain volatile and limited. (Nasdaq)

Net loss increased to $44.2 million in Q1 2026 from $22.6 million in Q1 2025, highlighting ongoing unprofitability and continued cash outflows, despite efforts to control expenses. (Nasdaq)

Future cash flows are highly dependent on a $250 million milestone from Jazz and a $15 million payment from BeOne tied to regulatory approvals for zanidatamab, introducing execution risk if these approvals are delayed or not granted. (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

Zymeworks Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Zymeworks Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZYME

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Net loss increased to $44.2 million in Q1 2026 from $22.6 million in Q1 2025, highlighting ongoing unprofitability and continued cash outflows, despite efforts to control expenses. (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.